Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Down 7.9% in November

Immix Biopharma, Inc. (NASDAQ:IMMX) saw a significant drop in short interest in the month of November. As of November 15th, there was short interest totalling 400,700 shares, a drop of 7.9% from the October 31st total of 434,900 shares. Based on an average daily volume of 126,100 shares, the days-to-cover ratio is presently 3.2 days. Currently, 2.5% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of Immix Biopharma in a research report on Thursday, October 3rd.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Immix Biopharma stock. Geode Capital Management LLC raised its position in shares of Immix Biopharma, Inc. (NASDAQ:IMMX) by 5.6% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 150,082 shares of the company’s stock after purchasing an additional 7,954 shares during the quarter. Geode Capital Management LLC owned about 0.55% of Immix Biopharma worth $224,000 as of its most recent SEC filing. 11.26% of the stock is currently owned by institutional investors.

Immix Biopharma Price Performance

NASDAQ:IMMX opened at $2.01 on Tuesday. Immix Biopharma has a 1 year low of $1.26 and a 1 year high of $7.75. The business has a fifty day moving average of $1.63 and a 200-day moving average of $1.93.

Immix Biopharma (NASDAQ:IMMX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.08). Analysts forecast that Immix Biopharma will post -0.64 earnings per share for the current year.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.